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Abstract
Background: Yoga can reduce blood pressure and has also been suggested to reduce inflammatory biomarkers
and metabolic risk factors for cardiovascular diseases (CVDs). We aimed to assess the benefit of two yoga
interventions on inflammatory biomarkers and metabolic risk factors in a high risk population in primary care.
Methods: Adult patients from a health care center in Sweden, with diagnosed hypertension, were invited to
undergo a baseline check at the health care center. Baseline check included standardized blood pressure
measurement, BMI and weight circumference measurements, blood sampling (hs-CRP, IL-6, FP-glucose, HbA1c,
cholesterol, TG, LDL and HDL) and a questionnaire on self-rated quality of life (WHOQOL-BREF). There were three
groups: 1) yoga class with yoga instructor; 2) yoga at home; and 3) a control group. In total, 83 patients were
included and matched at the group level for systolic blood pressure. A majority of the patients (92 %) were on
antihypertensive medication, which they were requested not to change during the study. After 12 weeks of
intervention, the assessments were performed again.
Results: We recorded no evidence that yoga altered inflammatory biomarkers or metabolic risk factors in our study
population. A total of 49 participants (59 %) met the criteria for metabolic syndrome.
Conclusion: The yoga interventions performed in our study did not affect inflammatory biomarkers or metabolic
risk factors associated with CVD in the study population of primary care patients with hypertension. Further
randomized trials are needed to elucidate the effects of yoga on CVD risk factors in this particular group.
Trail registration: NCT01302535, February 22, 2011.
Background
Yoga has been shown to reduce blood pressure (BP) in
several studies [1, 2]. In the YHIP study (Yoga’s effect on
Hypertension In Primary care) of yoga in primary health
care patients with hypertension, we showed that a short
home-based yoga program had an antihypertensive
effect and improved self-rated quality of life [3].
Persistent hypertension increases the risk of develop-
ing coronary heart disease, stroke and other cardiovascu-
lar diseases (CVDs), such as heart failure [4].
The metabolic biomarkers HbA1c, fasting plasma
(FP-) glucose, cholesterol, triglycerides (TGs) and low
density lipoproteins (LDL) are known risk factors for
CVDs and they are often associated with elevated
blood pressure as part of the metabolic syndrome [5, 6].
The opposite applies to high density lipoproteins (HDL),
where high levels seem to protect against CVD [7]. The
metabolic syndrome is a combination of certain risk fac-
tors that multiply the risk for heart disease, diabetes and
stroke [8]. To be diagnosed with metabolic syndrome, a
patient has to have at least three of the following five
conditions: Central obesity (waist circumference ≥ 102 cm
or ≥ 88 cm in male and female respectively); Blood pres-
sure ≥ 130/85 mmHg (or receiving drug therapy for
hypertension); Triglycerides ≥ 1.7 mmol/L (or receiving
therapy for hypertriglyceridemia); HDL < 1.0 mmol/L
or < 1.3 mmol/L in male and female respectively) and;
FP-glucose ≥5.6 mmol/L (or receiving drug therapy for
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hyperglycemia) [9]. Other studies have shown that dietary
intervention combined with yoga has a positive effect on
these metabolic biomarkers [9, 10].
The inflammatory blood tests high-sensitive C-reactive
protein (hs-CRP), interleukin 6 (IL-6) and interleukin 10
(IL-10) reflect the degree of inflammation in the body,
and high levels of hs-CRP (≥2.78 mg/L) and IL-6
(≥3.19 pg/mL) have been associated with increased risk
of death [11]. High levels of hs-CRP also seem to be a
predictor of cardiovascular events [12]. IL-10 is a cyto-
kine with anti-inflammatory effects. Some studies sug-
gest that yoga practice lowers the levels of hs-CRP and
IL-6 [12, 13] and increases levels of anti-inflammatory
proteins that in turn increases IL-10 levels [14]. Previous
studies also indicate a connection between hypertension
alone and systemic low-grade inflammation [15–17].
The effects of yoga on inflammatory biomarkers and
metabolic risk factors have, however, not been studied in
a primary care setting, although most patients with
hypertension and metabolic syndrome are treated in pri-
mary care. The aim of the study was to assess the benefit
of yoga on inflammatory biomarkers and metabolic risk




The YHIP study, from which the blood samples are
taken, was a prospective three-arm single-center study
of the effects of two types of yoga on BP and quality of
life [3]. There were two intervention groups and one
control group. The study was designed as a matched
controlled open clinical trial. Blood tests, BMI-, waist
circumference-, BP measurements and assessments of
lifestyle, health status and quality of life [18] were car-
ried out at baseline and after 12 weeks of intervention.
The groups were matched based on SBP after baseline
assessments.
Patients and recruitment
In January 2011, adult patients with diagnosed hyperten-
sion were identified by electronic charts search at
Svedala Health Care Center in Southern Sweden. Pa-
tients were invited to participate if their BP when most
recently measured at the health care center was between
120 and 160/80 and 100 mm Hg (e.g. normal, high nor-
mal and grade 1 hypertension levels). The patients who
agreed to participate were invited to the health care cen-
ter for baseline assessments. Patients with BP values of
120–179/<110 mmHg in the baseline check were eligible
for enrollment. Fasting blood samples were collected
and analyzed for HbA1c, FP-glucose, cholesterol, TGs,
HDL, LDL and hs-CRP. For each patient three cryo
tubes with blood were frozen for future analysis of IL-6
and IL-10. Baseline assessments and study question-
naires (lifestyle and health status survey and quality of
life were completed after written informed consent was
obtained from the participants.
All participants were requested not to change their
medication during the study, and any change in medica-
tion was registered at follow-up after 12 weeks. For fur-
ther details regarding patients and procedures please
refer to our previously published article [3].
Interventions
The yoga practiced in the YHIP study is a form of
Kundalini yoga developed at the Institute for Medical
Yoga (IMY) in Stockholm, Sweden [19]. Intervention
group 1 (28 persons) was divided into three smaller
groups, each consisting of 8–12 participants. Each group
met once a week for 60 min at the health care center to
practice yoga with a yoga instructor. The participants
were encouraged to practice yoga 30 min every day at
home between the yoga classes. The participants in
intervention group 2 (28 persons) were each given a
doctor’s appointment (20 min) during which they re-
ceived instructions for two yoga exercises to perform at
home for a combined total of 15 min a day. No changes
were made for the participants in the control group,
who received treatment as usual. In order to evaluate
compliance with yoga practice, each participant received
a yoga calendar in which to record when they did yoga.
For further details regarding the interventions please
refer to our previously published article [3].
Outcome
The main outcome measure was change in blood inflam-
matory and metabolic factor levels. We chose to analyze
inflammatory and metabolic factors with known or sus-
pected connections to CVD.
Measurements
Blood samples were collected at baseline and follow-up
for assessment of the following factors: HbA1c, FP-
glucose, cholesterol, TGs, HDL, LDL and hs-CRP. The
blood samples were drawn in the morning after a fast
since midnight.
HbA1c was analyzed using the Bio-Rad Variant II chro-
matographic method (reference range 31–44 mmol/mol)
by Swedish Mono-S high-performance ion-exchange liquid
chromatography. Due to an instrument change at the
laboratory during the intervention period, the following
were analyzed by different methods at baseline and
follow-up: FP-glucose, cholesterol, TGs and HDL. At
baseline, they were measured in plasma using an LX20
analyzer (Beckman Coulter Inc., Brea, CA). At follow-
up the above samples were analyzed using a cobas
6000 Analyzer (Roche Diagnostics, SA). LDL level
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was calculated using the Friedewald formula [20]. The re-
sults from follow-up were recalculated according to
regression equations provided by the laboratory to
compensate for any differences due to the change in
instrument.
The blood samples from baseline and follow-up were
used for IL-6 and IL-10 levels. Serum was isolated from
blood by centrifugation at 10,000 g at 4 °C for 10 min.
Samples were analyzed using Bio-Plex Pro human cyto-
kines assay (Bio-Rad Inc., Hercules, CA), according to
the manufacturer’s instructions with a few modifications.
Briefly, samples were diluted 1:3 in the sample diluent
provided with the kit and incubated with magnetic beads
coupled to specific antibodies. IL-6 and IL-10 were de-
tected with premixed detection antibody. Beads were
read on a Bio-Plex Suspension Array System and the
data were analyzed using Bio-Plex Manager™ software
(version 4.0). Absolute concentrations were measured
from a standard curve generated from nine serially di-
luted standards provided with the kit. Each sample was
analyzed in duplicate. Values are presented in pg/mL.
Each run included controls of known concentration for
each cytokine and a blank.
The health status and lifestyle survey was designed for
this study and is not validated. The survey contains
questions regarding comorbidity for diabetes and cardio-
vascular disease, smoking and drinking habits and phys-
ical activity.
The participants were instructed to mark the dates
they completed the yoga training. At follow-up, they
submitted their yoga calendars. The information in the
calendars was not controlled or questioned.
BP was measured in a standardized way, in a sitting
position after 5–10 min of rest with validated electronic
BP devices. The mean of two readings were calculated
(mean of three when the first and second reading dif-
fered by >5 mm Hg). The measurements were carried
out by trained nurses and care assistants.
Statistical analysis
Assuming a mean treatment difference in SBP of
5 mmHg between the yoga at home and control groups,
Fig. 1 CONSORT 2010 flow diagram
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a standard deviation of 6 mmHg and a drop-out rate of
30 %, 33 patients per group would provide 80 % power
to detect a statistically significant difference at the 5 %
level using a two-sided test.
One-way-ANOVA was used to determine whether
there were any significant differences in baseline data
between the groups. For the laboratory results that
were not normally distributed (FP-glucose, HbA1c,
hs-CRP, IL-10 and IL-6) we used the Kruskal-Wallis
test instead.
Differences in blood test parameters, BP and waist
circumference between baseline and follow-up in each
group were calculated by paired-samples Student’s t-test.
Differences in mean change between the yoga groups
and the control group were calculated by independent-
samples Student’s t-test. For the laboratory results that
were not normally distributed (FP-glucose, HbA1c,
hs-CRP, IL-6 and IL-10), the differences within and
between groups were calculated by Wilcoxon test
and Mann–Whitney U-test, respectively.
Version 22 of the IBM SPSS Statistics was used for the
statistical analysis.
All patients who attended follow-up appointments
were included in the analyses (as observed cases, OC).
We also made calculations in which patients who did
not perform yoga in 9/12 weeks or who changed
their medication were excluded (per-protocol set,
PPS). This criterion (9/12 weeks) was set up together
with the IMY founder, and it was not known to the
patients.
Ethical aspects
The study conforms to the principles outlined in the
Declaration of Helsinki and was approved by the
Regional Ethical Review Board in Lund, Sweden
(2010/728). The study was registered at ClinicalTrials.gov
(NCT01302535).
Results
Figure 1 shows the flow of participants through the
study. Of the 406 patients that where invited, 75 % (306)
declined to participate. At the baseline assessment 8 pa-
tients did not meet the inclusion criteria regarding blood
pressure. Only three participants where lost to follow-
up. The baseline characteristics of the patients are pre-
sented in Table 1. There was a predominance of women
in all three groups. A majority of the patients (72 %)
were overweight (body mass index (BMI) > 25 kg/m2)
and 60 % fulfilled the criteria for metabolic syndrome
(Table 1). All participants were diagnosed with hyperten-
sion at enrollment, and 92 % were on hypertensive
medication (Table 1).
Table 2 shows changes in blood parameters, systolic
BP (SBP) and diastolic BP (DBP) for the three groups.
No significant differences in change in SBP from base-
line between the yoga groups and the control group
were detected. However, the improvement in DBP for
the yoga at home group was significantly greater than
that for the control group. The increase in TG level was
significantly higher in the yoga class group compared to
the control group (+0.3 ± 0.6 vs. -0.3 ± 1.1 mmol/L). No
significant between-group differences in change from
baseline were detected for any of the other metabolic or
inflammatory blood factors or for waist circumference.
IL-10 was not detectable in a majority of the patients
(59 % at baseline and 63 % at follow up), and we there-
fore chose not to present the results.
Compliance with yoga practice (number of yoga
sessions) was lower in the yoga class group than in the
yoga at home group. However, the average total time
spent on yoga practice was higher in the yoga class group
than in the yoga at home group (about 24 h vs. 16 h).
We also did separate analyzes for those patients
whose BP decreased during the study (group one
and two), without finding any significant change in
any of the blood test before and after intervention
(data not shown).












n = 28 n = 28 n = 27
Mean (SD)a Mean (SD)a Mean
(SD)a
Age (years) 66.2 (7.7) 64.0 (10.3) 60.8 (11.0)
Female, number (%) 19 (67.9) 20 (71.4) 16 (59.3)
Metabolic syndrome, number
(%)
19 (67.9) 13 (48.1) 17 (63.0)
BMI (kg/m2) 29.7 (7.0) 28.5 (7.3) 28.8 (4.0)
Waist circumference, (cm) 100.4 (14.5) 97.0 (15.2) 100.9 (9.9)
Cholesterol (mmol/L) 5.2 (1.0) 5.4 (1.1) 5.3 (1.2)
LDL (mmol/L) 3.3 (0.9) 3.5 (1.0) 3.4 (1.1)
HDL (mmol/L) 1.3 (0.4) 1.5 (0.4) 1.4 (0.4)
TGs (mmol/L) 1.3 (1.0) 1.2 (0.8) 1.5 (1.2)
FP-glucose (mmol/L) 5.5 (0.8) 5.4 (1.6) 5.9 (2.3)
HbA1c (mmol/mol) 40.9 (10.5) 40.0 (8.5) 39.6 (10.1)
hs-CRP (mg/L) 5.0 (3.6) 2.9 (2.2) 3.6 (3.6)
IL-6 (pg/mL) 5.4 (3.3) 6.6 (5.1) 5.2 (3.6)
SBP (mmHg) 143.8 (14.9) 143.6 (14.2) 144.3
(14.5)
DBP (mmHg) 89.0 (7.6) 88.4 (6.2) 89.8 (7.3)
aUnless otherwise indicated
SBP Systolic blood pressure, DBP Diastolic blood pressure, LDL Low-density
lipoprotein, HDL High-density lipoprotein, TGs Triglycerides, hs-CRP
High-sensitivity C-reactive protein, IL-6 Interleukin 6
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Discussion
We recorded no evidence that yoga altered inflammatory
or metabolic biomarkers in our high risk population of
primary health care patients with hypertension. Al-
though previous studies have shown that yoga can re-
duce BP, our study could not detect any effects on the
other metabolic risk factors examined. The effects of
yoga on inflammatory biomarkers and metabolic risk
factors have not been studied previously in this particu-
lar group, although most patients with hypertension and
metabolic syndrome are treated in primary health care
and although there is increasing interest in and uptake
of yoga at community level.
Previous studies have shown that yoga practice can re-
duce levels of inflammatory factors such as hs-CRP and
IL-6 [21, 22]. However, none of these studies focused on
patients with hypertension or metabolic syndrome, but
on patients with chronic heart failure and breast cancer
respectively. Nor did they look at yoga’s effect on BP and
metabolic risk factors, but on exercise capacity, mood
and fatigue.
Other studies have looked at yoga’s effect on metabolic
parameters such as glucose and lipid levels in patients with
CVDs [8, 9, 22]. In these studies, in contrast to our study,
the yoga interventions were combined with other measures
such as changes in diet. Two out of the three studies
showed effects on the metabolic parameters [8, 9].
One explanation for the lack of significant results of
our study could be that the patients have already
influenced their biomarker levels through their medica-
tion (BP-lowering, anti-inflammatory aspirin and lipid-
lowering statins) to the extent that yoga has no additional
affect. There are studies suggesting that antihypertensive
treatment alone attenuates circulating levels of IL-6 [23].
Table 2 Change from baseline and difference vs. control for blood parameters, waist circumference, SBP and DBP
Intervention group 1 Intervention group 2 Group 3
Yoga class group Yoga at home group Control group
OC PPS OC PPS OC PPS
n = 28 n = 21 n = 26 n = 20 n = 26 n = 22
Mean (CI) Mean (CI) Mean (CI) Mean (CI) Mean (CI) Mean (CI)
Cholesterol (mmol/L) change from baseline 0.3 (0.1–0.5)* 0.2 (−0.0–0.4) −0.1 (−0.3–0.2) −0.1 (−0.2–0.4) 0.0 (−0.3–0.3) 0.1 (−0.3–0.4)
Difference vs. control 0.3 (−0.1–0.6) 0.1 (−0.2–0.5) −0.1 (−0.4–0.3) −0.1 (−0.4–0.3)
LDL (mmol/L) change from baseline 0.1 (−0.0–0.3) 0.1 (−0.1–0.3) −0.2 (−0.5–0.1) −0.1 (−0.3–0.2) 0.0 (−0.3–0.3) 0.0 (−0.3–0.3)
Difference vs. control 0.2 (−0.2–0.5) 0.1 (−0.3–0.5) −0.2 (−0.6–0.2) −0.1 (−0.5–0.4)
HDL (mmol/L) change from baseline 0.0 (−0.1–0.1) 0.0 (−0.1–0.1) 0.0 (−0.1–0.1) 0.0 (−0.0–0.1) 0.0 (−0.1–0.1) 0.0 (−0.1–0.1)
Difference vs. control −0.0 (−0.1–0.1) −0.0 (−0.2–0.1) −0.0 (−0.1–0.1) −0.0 (−0.1–0.1)
TGs (mmol/L) change from baseline 0.3 (0.1–0.5)* 0.3 (0.0–0.5)* 0.1 (−0.1–0.2) 0.1 (−0.1–0.2) −0.3 (−0.8–0.1) −0.3 (−0.8–0.2)
Difference vs. control 0.6 (0.1–1.1)* 0.6 (0.0–1.1)* 0.4 (−0.1–0.8) 0.4 (−0.1–0.9)
FP-glucose (mmol/L) change from baseline 0.1 (−0.2–0.4) 0.0 (−0.3–0.3) −0.1 (−0.3–0.2) −0.1 (−0.4–0.2) −0.4 (−1.1–0.3) −0.4 (−1.2–0.4)
Difference vs. control 0.5 (−0.2–1.3) 0.4 (−0.5–1.3) 0.4 (−0.4–1.1) 0.3 (−0.6–1.2)
HbA1c (mmol/mol) change from baseline −1.4 (−3.9–1.2) −1.9 (−4.9–1.1) −0.2 (−1.5–1.1) 0.3 (−1.3–1.9) −0.8 (−2.0–0.3) −0.9 (−2.2–0.4)
Difference vs. control −0.5 (−3.3–2.3) −1.0 (−4.0–2.0) 0.6 (−1.1–2.3) 1.2 (−0.7–3.2)
hs-CRP (mg/L) change from baseline −0.8 (−2.2–0.5) −0.6 (−2.3–1.1) 0.2 (−0.6–1.0) 0.1 (−1.0–1.2) 0.4 (−1.2–2.1) 0.5 (−1.4–2.4)
Difference vs. control −1.2 (−3.3–0.8) −1.1 (−3.6–1.3) −0.2 (−2.0–1.6) −0.4 (−2.7–1.8)
IL-6 (pg/mL) change from baseline −0.8 (−2.3–0.7) −0.8 (−2.4–0.9) 1.1 (−0.2–2.4) 1.1 (−0.4–2.5) 1.0 (−0.8–2.8) 1.2 (−0.7–3.1)
Difference vs. control −1.8 (−4.1–0.5) −2.0 (−4.5–0.5) 0.2 (−1.9–2.3) −0.1 (−2.5–2.2)
Waist circumf. (cm) change from baseline −0.4 (−1.9–1.1) −0.1 (−1.9–1.6) 0.6 (−1.5–2.7) 0.8 (−1.9–3.5) −0.0 (−2.3–2.3) 0.1 (−2.4–2.6)
Difference vs. control −0.4 (−3.1–2.2) −0.2 (−3.2–2.8) 0.6 (−2.4–3.7) 0.7 (−2.8–4.3)
SBP (mmHg)a change from baseline 0.3 (−5.8–6.4) −0.2 (−8.1–7.8) −6.8 (−11.6–2.11)* −6.1 (−11.7–0.7) −2.3 (−7.6–3.0) −1.9 (−7.7–4.1)
Difference vs. control 2.6 (−5.4–10.5) 1.7 (−7.9–11.1) −4.4 (−11.5–2.4) −4.2 (−12.3–3.5)
DBP (mmHg)a change from baseline 0.2 (−3.2–3.7) 0.3 (−3.9–4.3) −4.4 (−7.3–1.3)* −3.9 (−7.3–0.1) 0.8 (−3.2–4.4) 1.0 (−3.2–4.9)
Difference vs. control −0.6 (−5.3–4.6) −0.8 (−6.2–5.0) −5.2 (−9.6–0.2)* −4.9 (−9.9–0.1)*
*p < 0.05 vs. control group
apreviously published results [3]
CI Confidence interval, DBP Diastolic blood pressure, HDL High-density lipoprotein, hs-CRP High-sensitivity C-reactive protein, LDL Low-density lipoprotein,
OC Observed cases, PPS Per-protocol set, SBP Systolic blood pressure, SE Standard error of the mean, TGs Triglycerides
The PPS consists of all patients who practiced yoga at least once a week for 9 weeks or more and who had no change in medication during the study period
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Since 92 % of the study participants were already on anti-
hypertensive medication at baseline, the possibility of fur-
ther reducing IL- 6 levels could thus have been adversely
affected.
Another reason for the lack of effect is that there are
many different yoga schools, and we can’t exclude the
possibility that certain types of yoga have greater impact
on inflammatory and metabolic blood factors. The yoga
intervention design in the above described studies varied
and the length of the intervention ranged from 8 to 12
weeks, making it difficult to compare the interventions
in terms of effectiveness. However, the findings could
also mean that yoga cannot contribute to improve the
metabolic profile or decrease inflammation in these
patients.
The study has a number of strengths. Primarily, it is
more comprehensive compared to other similar yoga
studies.
It also investigated the effect of yoga on a large num-
ber of biomarkers and risk factors. The study focused on
a high risk population, where there is often a need for
additional treatment to achieve treatment goals.
Strengths of this study also include excellent adherence
with minimal attrition: only 3 of 83 patients failed to at-
tend the follow-up.
On the other hand the study has a number of limita-
tions. Our study is limited to a single form of yoga [19].
It may be that other schools of yoga or other yoga pro-
grams have a better impact on the biomarkers and risk
factors that we studied. The participants were matched
at a group level and not randomized. However, since
there was no change in blood factor levels in any of the
groups throughout the study, it is unlikely that
randomization would have made a difference to the out-
come in this case. Our rationale for matching the groups
was that we wanted to ensure similar SBP values at base-
line. A weakness of the study also concerns the self-
reported data (yoga calendar), which is a problem in all
studies of this kind. Due to an instrument change at the
laboratory during the intervention period, four out of
nine blood samples were analyzed by different instru-
ments at baseline and follow up. Even though we had
regression equations to compensate for the differences, we
cannot exclude the possibility that the instrument change
influenced the results of these tests to some extent.
For yoga to be considered a viable and accepted treat-
ment alternative for patients with high BP and increased
risk of CVD, we need research that can not only show
yoga’s effects on BP and on CVD related risk factors, but
also help us understand its mechanism of action.
Conclusion
Although yoga can lower BP and increase quality of life,
our study, which is the first in this particular group of
patients, could not confirm that the yoga performed had
any effect on the biomarkers examined. Further research
is needed to confirm the antihypertensive effect of yoga
and to clarify how yoga affects BP and other risk factors
for CVDs in hypertensive patients in a primary health
care setting.
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